Comparative Pharmacology
Head-to-head clinical analysis: LEUPROLIDE ACETATE FOR DEPOT SUSPENSION versus LUPRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEUPROLIDE ACETATE FOR DEPOT SUSPENSION versus LUPRON.
LEUPROLIDE ACETATE FOR DEPOT SUSPENSION vs LUPRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Leuprolide acetate is a synthetic gonadotropin-releasing hormone (GnRH) agonist. Continuous administration suppresses pituitary gonadotropin secretion, leading to decreased luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby reducing gonadal steroid production (testosterone and estrogen).
Gonadotropin-releasing hormone (GnRH) agonist. Chronic administration suppresses pituitary gonadotropin secretion, leading to decreased testosterone and estradiol levels.
3.75 mg IM every 4 weeks or 11.25 mg IM every 12 weeks for advanced prostate cancer; 3.75 mg IM every month for endometriosis or uterine leiomyomas; 7.5 mg IM monthly for central precocious puberty.
3.75 mg intramuscularly once monthly or 11.25 mg intramuscularly once every 3 months. For endometriosis, 3.75 mg intramuscularly monthly for up to 6 months. For central precocious puberty, 0.3 mg/kg intramuscularly every 28 days.
None Documented
None Documented
3-4 hours for subcutaneous injection; after depot injection, initial burst release followed by slow release with apparent half-life of approximately 3-4 weeks due to absorption rate-limited elimination.
Terminal half-life approximately 3 hours after subcutaneous administration; in patients with renal impairment, half-life may be prolonged
Primarily renal (metabolites), approximately 5% unchanged; fecal elimination accounts for <5%.
Renal (primarily as metabolites), <5% unchanged; fecal ~5%
Category D/X
Category C
GnRH Agonist
GnRH Agonist